28 April 2026: The 2026 Annual General Meeting of Aker BioMarine ASA was held
today as a digital meeting with online participation.
All resolutions were made in accordance with the proposals set out in the
meeting notice.
The minutes of the meeting are attached and available at
www.akerbiomarine.com/agm.
The general meeting re-elected Ola Snøve as Chair of the Board, re-elected Cilia
Holmes Indahl and Frank O. Reite as members of the Board, and re-elected Kjell
Inge Røkke as deputy member of the Board. Kathryn M. Baker was elected as a new
member of the Board in replacement of Anne Harris and Kimberly Mathisen, thereby
reducing the number of shareholder-elected board members from five to four. All
were elected for a term of one year, until the Company's annual general meeting
in 2027. The Board of Aker BioMarine ASA now consists of:
- Ola Snøve, Chair of the Board
- Cilia Holmes Indahl
- Frank O. Reite
- Kathryn M. Baker
- Kjell Inge Røkke (Deputy Member)
For further information, please contact
Lars Jacobsen, General Counsel
Mobile: +47 906 05 306
Email: lars.jacobsen@akerbiomarine.com
About Aker BioMarine
Aker BioMarine is a leading human health and nutrition innovator that develops
krill-derived products for consumer health and nutrition. Krill is a natural,
powerful, and health-promoting source of nutrients from the pristine waters of
Antarctica, and Aker BioMarine has a unique position in its industry. The
ingredient portfolio consists of Superba Krill Oil, Lysoveta, Revervia, and PL+,
as well as the consumer brand, Kori Krill. The innovative approach also extends
into the spin-offs AION (reduce and recycle plastic waste across industries) and
Understory (a protein brand). Aker BioMarine is listed on the Oslo Stock
Exchange (AKBM). More information is available at www.akerbiomarine.com.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.